Application of a serum protein in screening and diagnosis of novel coronavirus infection

Through mass spectrometry-based PLGLB1 protein detection, the false negative and false positive problems in existing COVID-19 detection methods are solved, and accurate screening and diagnosis of COVID-19 patients is achieved, with higher sensitivity and stability.

CN115704802BActive Publication Date: 2024-11-19BEIJING PROTEOME RES CENT +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210959714.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-08-11
Filing Date
2022-08-11
Publication Date
2024-11-19
Estimated Expiration
2042-08-11

AI Technical Summary

Technical Problem

The existing COVID-19 detection methods have false negative and false positive results, and the positivity rate of serological examinations is low in the early stages of the disease, and new detection methods are needed to improve detection accuracy.

Method used

Based on mass spectrometry technology, by detecting the relative content of PLGLB1 protein, qualitative and quantitative detection of proteins is performed using tandem mass spectrometry tag (TMT) method and targeted quantitative method, and the determination is carried out in combination with a computing device. If the relative content of PLGLB1 protein reaches or exceeds a specific threshold, It is determined to be a COVID-19 infection patient.

Benefits of technology

Accurate screening and diagnosis of COVID-19 patients has been achieved, with a sensitivity of 99% and a specificity of 100% when distinguishing asymptomatic from early patients, with a higher sensitivity and stability compared with nucleic acid testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115704802B_ABST
    Figure CN115704802B_ABST
Patent Text Reader

Abstract

The present disclosure relates to a system and method for screening and diagnosing novel coronavirus pneumonia based on PLGLB1 protein, the use of materials for detecting PLGLB1 protein in preparing a kit for screening and diagnosing novel coronavirus pneumonia, the use of a device for detecting PLGLB1 protein in preparing a system for screening and diagnosing novel coronavirus pneumonia, and the use of stable isotope-labeled peptides in preparing a kit based on mass spectrometry for screening and diagnosing novel coronavirus pneumonia. The present disclosure discovers for the first time that PLGLB1 protein can be used as a serum diagnostic marker for the entire course of novel coronavirus pneumonia patients, and has higher detection sensitivity and stability.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese Patent Application No. 202110921349.9 filed on August 11, 2021, the entire contents of which are incorporated herein by these references for all purposes. Technical Field

[0003] The present disclosure relates to the field of biomedicine, and specifically, to a system and method for screening and diagnosing novel coronavirus infection based on PLGLB1 protein, use of materials for detecting PLGLB1 protein in preparing a kit for screening and diagnosing novel coronavirus infection, use of a device for detecting PLGLB1 protein in preparing a system for screening and diagnosing novel coronavirus infection, and use of stable isotope-labeled peptides in preparing a kit based on mass spectrometry for screening and diagnosing novel coronavirus infection. Background Art

[0004] Corona Virus Disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was declared a pandemic by the World Health Organization on March 11, 2020. Currently, the novel coronavirus infection has become a global threat.

[0005] Detection of COVID-19 patients is very important for epidemic control. The current clinical diagnosis of COVID-19 is mainly based on etiological testing and serological examinations. The etiological examination uses the reverse transcription polymerase chain reaction (RT-PCR) method to detect novel coronavirus nucleic acid in nasopharyngeal swabs, sputum and other lower respiratory tract secretions, blood, feces, urine and other specimens. However, incorrect sampling operations, low viral load in the sample collection area or collection time, irregular transportation process and viral mutations often lead to false negative results. Serological examination is the detection of novel coronavirus-specific IgM antibodies and IgG antibodies, but the positive rate is low within 1 week of onset, and false positive results may occur due to the presence of interfering substances in the body or specimen reasons. Therefore, new COVID-19 detection methods are still urgently needed. Summary of the invention

[0006] The purpose of the present disclosure is to provide a new COVID-19 detection method.

[0007] The inventors of the present disclosure discovered a highly sensitive and highly specific biomarker, namely, PLGLB1 protein, in serum samples of COVID-19 patients through large-scale comparative proteomics technology based on mass spectrometry, thereby obtaining the technical solution of the present disclosure.

[0008] In a first aspect, the present disclosure provides a mass spectrometry-based system for screening and diagnosing novel coronavirus infection, the system comprising a device for detecting PLGLB1 protein, the device for detecting PLGLB1 protein comprising a mass spectrometer, and the mass spectrometer is configured to be capable of performing qualitative and quantitative detection of proteins using a tandem mass tagging (TMT) method and / or a targeted quantitative method.

[0009] Optionally, the system further includes a computing device, an input device for inputting the expression amount of PLGLB1 protein, and an output device for outputting the discrimination between normal people and patients infected with the novel coronavirus at different stages of the disease course; wherein the computing device includes a memory and a processor, the memory stores a computer program, and the processor is configured to execute the computer program stored in the memory to achieve the following discrimination: if the relative content of PLGLB1 protein in the blood sample of the person to be tested who does not have fever and / or cough symptoms is greater than or equal to 0.67, then the person to be tested who does not have fever / cough symptoms or a candidate is judged to be a patient infected with the novel coronavirus; and / or, if the relative content of PLGLB1 protein in the serum of the person to be tested who has fever and / or cough symptoms is greater than or equal to 0.77, then the person to be tested who has fever and / or cough symptoms or a candidate is judged to be a patient infected with the novel coronavirus; wherein the relative content is defined as the ratio obtained by dividing the abundance of PLGLB1 protein in a sample by the average abundance of the protein; the average abundance refers to the abundance in a mixed sample of a tandem mass tag (TMT) method.

[0010] In a second aspect, the present disclosure provides a method for screening and diagnosing novel coronavirus infection based on mass spectrometry, the method comprising the following steps: S1, obtaining a blood sample of a person to be tested; S2, based on mass spectrometry, using a tandem mass tagging (TMT) method and / or a targeted quantitative method, wherein the targeted quantitative method is parallel reaction monitoring (PRM), multiple reaction monitoring (MRM) or selective reaction detection (SRT). S3, making the following judgment: if the relative content of PLGLB1 protein in the blood sample of the test person who does not have fever and / or cough symptoms is greater than or equal to 0.67, the test person who does not have fever / cough symptoms is judged to be a patient or candidate for novel coronavirus infection; and / or, if the relative content of PLGLB1 protein in the serum of the test person who has fever and / or cough symptoms is greater than or equal to 0.77, the test person or candidate for novel coronavirus infection is judged to be a patient with fever and / or cough symptoms; wherein the relative content is defined as the ratio of the abundance of PLGLB1 protein in a certain sample divided by the average abundance of the protein; and the average abundance refers to the abundance in a mixed sample of a tandem mass tagging (TMT) method.

[0011] In a third aspect, the present disclosure provides the use of materials for detecting PLGLB1 protein in preparing a kit for screening and diagnosis of novel coronavirus infection.

[0012] Optionally, the material for detecting PLGLB1 protein is a material that can detect PLGLB1 protein in a sample from human blood; preferably, the kit contains at least one of a colloidal gold test strip, an ELISA reagent, and a chemiluminescent reagent, and the material for detecting PLGLB1 protein is at least one of an antibody against PLGLB1 protein or peptide, a nucleic acid aptamer that specifically binds to PLGLB1 protein or peptide, a peptide nucleic acid that specifically binds to PLGLB1 protein or peptide, other substances that can specifically bind to PLGLB1 protein or peptide, and a PLGLB1 protein or peptide standard.

[0013] In a fourth aspect, the present disclosure provides the use of a device for detecting PLGLB1 protein in preparing a system for screening and diagnosing novel coronavirus infection.

[0014] Optionally, the device for detecting PLGLB1 protein is a device capable of qualitatively and quantitatively detecting PLGLB1 protein in a sample from human blood, such as a signal reading device such as a mass spectrometer, a spectrophotometer, a chemiluminescence analyzer, etc.

[0015] Optionally, the device for detecting PLGLB1 protein comprises a mass spectrometer, and the mass spectrometer is configured to be capable of performing qualitative and quantitative detection of proteins using a TMT method and / or a PRM / MRM / SRM method.

[0016] Optionally, the amino acid sequence of the PLGLB1 protein is shown in SEQ ID NO: 1, and when the tandem mass tagging (TMT) method is used, the detected peptide segment is the peptide segment of the PLGLB1 protein; when the PRM / MRM / SRM method is used for protein qualitative and quantitative detection, the detected matching peptide segment includes the PLGLB1 protein-specific peptide segment, and the amino acid sequence of the PLGLB1 protein-specific peptide segment includes but is not limited to SEQ ID NO: 2 and SEQ ID NO: 3.

[0017] In a fifth aspect, the present disclosure provides the use of stable isotope labeling in the preparation of standard peptides in a mass spectrometry-based kit for screening and diagnosis of novel coronavirus infection, wherein the stable isotope labeling includes: arginine R is labeled with C13 and / or N15, and / or, lysine K is labeled with C13 and / or N15; the amino acid sequence of the standard peptide is a fragment of the amino acid sequence of the PLGLB1 protein.

[0018] Through the above technical scheme, the present invention distinguishes between normal people without fever and / or cough symptoms and early novel coronavirus infection patients, and the receiver operating characteristic (ROC) curve analysis results show that the area under the curve (AUC) reaches 0.99, the sensitivity is 99%, and the specificity is 100%; when distinguishing between patients with fever and / or cough symptoms and early novel coronavirus infection patients, the AUC reaches 0.99, the sensitivity is 99%, and the specificity is 100%.

[0019] It is worth noting that in the new coronavirus nucleic acid test conducted on the same day as the collection of serum samples from patients infected with the new coronavirus, 29.2% of the patients were negative (excluding the test results after the nucleic acid turned negative before discharge and the nucleic acid test was not performed on the day of sampling), and before the nucleic acid test turned negative, most patients had fluctuating nucleic acid test results, while the PLGLB1 protein maintained extremely high detection sensitivity in serum samples at multiple stages of the disease (including the acute phase, progressive phase, and recovery phase). This result shows that compared with the new coronavirus nucleic acid test, the PLGLB1 protein has higher detection sensitivity and stability for patients infected with the new coronavirus.

[0020] Other features and advantages of the present disclosure will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The accompanying drawings are used to provide a further understanding of the present disclosure and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present disclosure but do not constitute a limitation of the present disclosure. In the accompanying drawings:

[0022] Figure 1 This is a scatter plot of the relative quantitative levels of PLGLB1 protein in the serum of the normal group, fever / cough patient group, and early novel coronavirus infection patient group.

[0023] Figure 2 The results of ROC curve analysis of the relative quantitative levels of PLGLB1 protein in the serum of the normal group and the early novel coronavirus infection group (A) and the fever / cough group and the early novel coronavirus infection group (B).

[0024] Figure 3 This is a scatter plot of the relative quantitative levels of PLGLB1 protein in the serum of the normal group, fever / cough patient group, and novel coronavirus infection patient group at different stages of the disease course.

[0025] Figure 4 The results of ROC curve analysis of the relative quantitative level of PLGLB1 protein in serum of the normal group and the patients with novel coronavirus infection at different stages of the disease course (A) and the patients with fever / cough and the patients with novel coronavirus infection at different stages of the disease course (B).

[0026] Figure 5 This is the standard curve of the peptide segment shown in SEQ ID NO:2. DETAILED DESCRIPTION

[0027] The specific implementation of the present disclosure is described in detail below in conjunction with the accompanying drawings. It should be understood that the specific implementation described herein is only used to illustrate and explain the present disclosure, and is not used to limit the present disclosure.

[0028] In a first aspect, the present disclosure provides a mass spectrometry-based system for screening and diagnosing novel coronavirus infection, the system comprising a device for detecting PLGLB1 protein, the device for detecting PLGLB1 protein comprising a mass spectrometer, and the mass spectrometer is configured to be capable of performing qualitative and quantitative detection of proteins using a tandem mass tagging (TMT) method and / or a targeted quantitative method.

[0029] In the present disclosure, PLGLB1 refers to Plasminogen-like protein B (PLGLB1 or PLGLB2, hereinafter referred to as PLGLB1), whose NCBI GENE ID is 5343, UniProt number is Q02325, and amino acid sequence is:

[0030] MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGPSLFSVTKKQLGAGSREECAAKCEEDKEFTCRAFQYHSKEQQCVIMAENRKSSIIIRMRDAVLFEK (SEQ ID NO: 1).

[0031] Optionally, the system further includes a computing device, an input device for inputting the expression amount of PLGLB1 protein, and an output device for outputting the discrimination between normal people and patients infected with the novel coronavirus at different stages of the disease course; wherein the computing device includes a memory and a processor, the memory stores a computer program, and the processor is configured to execute the computer program stored in the memory to achieve the following discrimination: if the relative content of PLGLB1 protein in the blood sample of the person to be tested who does not have fever and / or cough symptoms is greater than or equal to 0.67, then the person to be tested who does not have fever / cough symptoms or a candidate is judged to be a patient infected with the novel coronavirus; and / or, if the relative content of PLGLB1 protein in the serum of the person to be tested who has fever and / or cough symptoms is greater than or equal to 0.77, then the person to be tested who has fever and / or cough symptoms or a candidate is judged to be a patient infected with the novel coronavirus; wherein the relative content is defined as the ratio obtained by dividing the abundance of PLGLB1 protein in a sample by the average abundance of the protein; the average abundance refers to the abundance in a mixed sample of a tandem mass tag (TMT) method.

[0032] In a second aspect, the present disclosure provides a method for screening and diagnosing novel coronavirus infection based on mass spectrometry, the method comprising the following steps: S1, obtaining a blood sample of a person to be tested; S2, based on mass spectrometry, using a tandem mass tagging (TMT) method and / or a targeted quantitative method, wherein the targeted quantitative method is parallel reaction monitoring (PRM), multiple reaction monitoring (MRM) or selective reaction detection (SRT). S3, making the following judgment: if the relative content of PLGLB1 protein in the blood sample of the test person who does not have fever and / or cough symptoms is greater than or equal to 0.67, the test person who does not have fever / cough symptoms is judged to be a patient or candidate for novel coronavirus infection; and / or, if the relative content of PLGLB1 protein in the serum of the test person who has fever and / or cough symptoms is greater than or equal to 0.77, the test person or candidate for novel coronavirus infection is judged to be a patient with fever and / or cough symptoms; wherein the relative content is defined as the ratio of the abundance of PLGLB1 protein in a certain sample divided by the average abundance of the protein; and the average abundance refers to the abundance in a mixed sample of a tandem mass tagging (TMT) method.

[0033] In a third aspect, the present disclosure provides the use of materials for detecting PLGLB1 protein in preparing a kit for screening and diagnosis of novel coronavirus infection.

[0034] Optionally, the material for detecting PLGLB1 protein is a material that can detect PLGLB1 protein in a sample from human blood; preferably, the kit contains at least one of a colloidal gold test strip, an ELISA reagent, a chemiluminescent reagent, etc., and the material for detecting PLGLB1 protein is at least one of an antibody against PLGLB1 protein or peptide, a nucleic acid aptamer that specifically binds to PLGLB1 protein or peptide, a peptide nucleic acid that specifically binds to PLGLB1 protein or peptide, other substances that can specifically bind to PLGLB1 protein or peptide, and a PLGLB1 protein or peptide standard.

[0035] In a fourth aspect, the present disclosure provides the use of a device for detecting PLGLB1 protein in preparing a system for screening and diagnosing novel coronavirus infection.

[0036] Optionally, the device for detecting PLGLB1 protein is a device capable of qualitatively and quantitatively detecting PLGLB1 protein in a sample from human blood, such as a signal reading device such as a mass spectrometer, a spectrophotometer, a chemiluminescence analyzer, etc.

[0037] Optionally, the device for detecting PLGLB1 protein comprises a mass spectrometer, and the mass spectrometer is configured to be capable of performing qualitative and quantitative detection of proteins using a tandem mass tagging (TMT) method and / or a PRM / MRM / SRM method.

[0038] Optionally, the amino acid sequence of the PLGLB1 protein is shown in SEQ ID NO: 1, and when the tandem mass tagging (TMT) method is used, the detected peptide segment is the peptide segment of the PLGLB1 protein; when the PRM / MRM / SRM method is used for protein qualitative and quantitative detection, the detected matching peptide segment includes the PLGLB1 protein-specific peptide segment, and the amino acid sequence of the PLGLB1 protein-specific peptide segment includes but is not limited to SEQ ID NO: 2 and SEQ ID NO: 3. The peptide segment of the PLGLB1 protein can specifically be a peptide segment produced by protease cleavage of the PLGLB1 protein, and the protease includes trypsin and / or pepsin, etc.

[0039] In the present disclosure, the amino acid sequence of the PLGLB1 protein-specific peptide segment is EQQCVIMAENR (SEQ ID NO: 2) or QLGAGSREECAAK (SEQ ID NO: 3).

[0040] In a fifth aspect, the present disclosure provides the use of stable isotope labeling in the preparation of standard peptides in a mass spectrometry-based kit for screening and diagnosis of novel coronavirus infection, wherein the stable isotope labeling includes: arginine R is labeled with C13 and / or N15, and / or, lysine K is labeled with C13 and / or N15; the amino acid sequence of the standard peptide is a fragment of the amino acid sequence of the PLGLB1 protein.

[0041] The technical solutions of the present disclosure are further described in detail below through examples. The experimental methods used in the following examples are conventional methods unless otherwise specified.

[0042] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0043] Explanations of terms used in the following embodiments:

[0044] The receiver operating characteristic (ROC) curve reflects the balance between sensitivity and specificity. The area under the ROC curve is an important indicator of test accuracy. The area under the ROC curve (AUC) of each test is calculated and compared. The larger the area, the greater the diagnostic value of the test.

[0045] Sensitivity (true positive rate): The percentage of people who are actually sick but are correctly diagnosed as sick according to the test standards. The higher the sensitivity, the better. The ideal sensitivity is 100%.

[0046] Specificity (true negative rate): The percentage of people who are actually disease-free but are correctly judged as disease-free according to the test standards. The higher the specificity, the better. The ideal specificity is 100%.

[0047] Example 1

[0048] This example is used to illustrate the collection of serum samples. Normal group: 14 normal people (N); Fever / cough patient group: 13 non-novel coronavirus-infected patients with fever and / or cough symptoms; Novel coronavirus-infected patient group: 79 novel coronavirus-infected patients (79 serum samples were collected from each patient in the early stage of the disease, and a total of 181 serum samples were collected at different stages of the disease).

[0049] Among them, normal human serum comes from normal physical examination subjects; fever / cough patients and new coronavirus infection patients are all serum samples of clinically confirmed patients. Fever refers to a body temperature higher than 37.5°C, and the diagnostic criteria for new coronavirus infection refer to the "Diagnosis and Treatment Plan for New Coronavirus Pneumonia (2020 Trial Version 5)" issued by the National Health Commission.

[0050] Example 2

[0051] This example is used to illustrate the proteomic detection of serum samples.

[0052] 1. Perform TMT proteomics testing on the above serum samples:

[0053] 1. Protein enzymatic hydrolysis: After the serum samples were sterilized at 56°C for 30 minutes, 5 μl of each sample was added to 50 μl of lysis buffer (8M urea, 50mM Tris-Cl, pH 7.4) and denatured at 32°C for 30 minutes. 10mM dithiothreitol was added to the sample for reduction at 37°C for 1 hour, and then 40mM iodoacetamide was added for alkylation at room temperature in the dark for 30 minutes. After diluting 4 times with 50mM ammonium bicarbonate, trypsin (Promega, 1 / 50 of the protein amount) was added to react for 12 hours, and an equal amount of trypsin was added again to react for 4 hours. After adding 0.1% trifluoroacetic acid to the peptide sample, it was desalted and dried using a homemade C18 column (Agela Technologies).

[0054] 2. TMT labeling: 200 μl of 200 mM TEAB was added to each sample to dissolve the peptides, 25 μg of peptides were taken out and labeled with TMTpro 16plex labeling reagent (Thermo Fisher Scientific), and the sample of all samples mixed in equal amounts was used as the internal standard. All samples in each TMT were combined and vacuum dried.

[0055] 3. Liquid chromatography separation and mass spectrometry data acquisition: The high performance liquid chromatograph was L-3000HPLC (RIGOL), the chromatographic column was XBridge Peptide BEH C18 (5 μm, 25 cm × 4.6 mm) (Waters), and the TMT-labeled peptides were gradient separated in a mobile phase of acetonitrile and water (pH adjusted to 10 with ammonia water) (5% to 35% acetonitrile, flow rate of 1 ml / min). The separated peptides were combined into 40 components and dried. The samples were re-dissolved in 2% acetonitrile / 0.1% formic acid solution and subjected to mass spectrometry analysis in DDA mode by Q Exactive HF mass spectrometer (Thermo Fisher Scientific) and nano-HPLC chromatograph (UltiMate 3000LC). The LC-MS parameters were as follows: mobile phase A was 0.1% formic acid in water, mobile phase B was 80% acetonitrile and 0.1% formic acid in water, liquid phase gradient was 42 min (mobile phase B from 4% to 40%), flow rate was 700 nl / min (analytical column 1.9 μm, 150 mm × 150 μm). The mass spectrometer was in full scan mode (m / z 300–1400, resolution 120,000), and the 15 ions with the strongest primary mass spectrometry signals were detected by secondary mass spectrometry (resolution 60,000).

[0056] 4. Mass spectrometry data analysis: Proteome Discoverer software (version 2.4.1.15, Thermo Fisher Scientific) was used to search the raw mass spectrometry data. The databases used were the human library (UniProtKB, downloaded on August 8, 2020, containing 20,289 protein sequences) and the SARS-CoV-2 virus library (NCBI, version NC_045512.2). The search parameters were as follows: the parent ion mass tolerance was 20 ppm; the daughter ion mass tolerance was 0.02 Da; the fixed modification was carbamidomethylation of cysteine; the variable modifications were TMTpro at lysine and the N-terminus of the peptide, oxidation of methionine and acetylation of the N-terminus of the peptide; a maximum of two missed cleavage sites were allowed; the FDR at the protein and peptide levels was 1%. The protein intensity of each sample in the same TMT batch was normalized by dividing it by the internal standard.

[0057] 5. SPSS16.0 software was used to perform Mann-Whitney U test and ROC curve analysis on the relative quantitative level of PLGLB1 protein between the disease group and the control group.

[0058] 2. Parallel Reaction Monitoring (PRM) of serum samples from a patient infected with the novel coronavirus and a normal person

[0059] 1. Protein enzymatic hydrolysis: After the serum samples were sterilized at 56°C for 30 minutes, 5 μl of each sample was added to 50 μl of lysis buffer (8M urea, 50mM Tris-Cl, pH 7.4) and denatured at 32°C for 30 minutes. 10mM dithiothreitol was added to the sample for reduction at 37°C for 1 hour, and then 40mM iodoacetamide was added for alkylation at room temperature in the dark for 30 minutes. After diluting 4 times with 50mM ammonium bicarbonate, trypsin (Promega, 1 / 50 of the protein amount) was added to react for 12 hours, and an equal amount of trypsin was added again to react for 4 hours. After adding 0.1% trifluoroacetic acid to the peptide sample, it was desalted and dried using a homemade C18 column (Agela Technologies).

[0060] 2. Mass spectrometry data acquisition for PRM relative quantification: The peptide samples after enzyme digestion were added with equal amounts of stable isotope-labeled standard peptides EQQCVIMAENR (SEQ ID NO: 2) and QLGAGSREECAAK (SEQ ID NO: 3) (arginine R and lysine K are C13N15-labeled heavy-labeled amino acids), and mass spectrometry analysis was performed in PRM mode using a Q Exactive HF mass spectrometer (Thermo Fisher Scientific) and a nano-HPLC chromatograph (UltiMate 3000LC).

[0061] 3. Establish a quantitative standard curve for the peptide EQQCVIMAENR (SEQ ID NO: 2): Take equal amounts of the above normal human serum enzymatically digested peptide samples and add different amounts of the stable isotope-labeled standard peptide EQQCVIMAENR (SEQ ID NO: 2), and perform mass spectrometry analysis in PRM mode using a Q Exactive HF mass spectrometer (Thermo Fisher Scientific) and a nano-HPLC chromatograph (UltiMate 3000LC).

[0062] 4. Mass spectrometry data analysis: The mass spectrometry PRM raw data produced by the above experiment were analyzed using Skyline software (MacCoss Lab) to obtain the quantitative abundance results of the peptides EQQCVIMAENR (SEQ ID NO: 2) and QLGAGSREECAAK (SEQ ID NO: 3) in the sample, as well as the standard curve of the peptide EQQCVIMAENR (SEQ ID NO: 2).

[0063] 3. Results

[0064] TMT proteomics identified two peptides of PLGLB1 protein, EQQCVIMAENR (SEQ ID NO: 2) and QLGAGSREECAAK (SEQ ID NO: 3). The results of protein level analysis showed that the mean ± standard deviation of the relative quantitative abundance of PLGLB1 protein in the serum of 14 normal people was 0.50 ± 0.10, 0.50 ± 0.12 in the fever / cough patient group, 1.09 ± 0.16 in the early novel coronavirus infection patient group, and 1.13 ± 0.18 in the novel coronavirus infection patient group at different stages of the disease. The relative abundance of PLGLB1 protein in each group of samples was statistically analyzed (Mann-Whitney U test), and it was found that compared with the normal group and the fever / cough patient group, the serum PLGLB1 protein was significantly upregulated in the early novel coronavirus infection patient group and the novel coronavirus infection patient group at different stages of the disease (p < 0.0001) ( Figure 1 and Figure 3 ).

[0065] The normal group was used as the control group, and the early novel coronavirus infection patient group was used as the disease group. The ROC curve analysis of the serum PLGLB1 protein level was performed, and the area under the curve AUC of the early novel coronavirus infection patient group was 0.99 ( Figure 2 The sensitivity is 99% and the specificity is 100%. It is particularly noteworthy that asymptomatic infected persons who are most easily confused with normal persons are also correctly identified. The fever / cough patient group is used as the control group, and the early novel coronavirus infection patient group is used as the disease group. The AUC for identifying early novel coronavirus infection patients is 0.99 (as shown in Figure 1). Figure 2 The sensitivity was 99% and the specificity was 100%.

[0066] The normal group was used as the control group, and the patients with novel coronavirus infection at different stages of the disease were used as the disease group. The ROC curve analysis of the serum PLGLB1 protein level was performed, and the area under the curve AUC of the patients with novel coronavirus infection was 0.99 (e.g. Figure 4 The sensitivity is 99% and the specificity is 100%. It is particularly noteworthy that asymptomatic infected persons who are most easily confused with normal people are also correctly identified. The fever / cough patient group is used as the control group, and the new coronavirus infection patient group at different stages of the disease course is used as the disease group. The AUC for identifying new coronavirus infection patients is 0.99 (as shown in Figure 1). Figure 4 The sensitivity was 98% and the specificity was 100%.

[0067] When distinguishing between normal people and patients infected with the novel coronavirus at different stages of the disease, if the relative content of PLGLB1 protein in the serum of the person to be tested is greater than or equal to 0.67, the person to be tested is or is a candidate for a patient infected with the novel coronavirus. When distinguishing between patients with fever / cough and patients infected with the novel coronavirus at all stages of the disease, if the relative content of PLGLB1 protein in the serum of the person to be tested is greater than or equal to 0.77, the person to be tested is or is a candidate for a patient infected with the novel coronavirus.

[0068] The relative content threshold used in the above discrimination is the threshold corresponding to the maximum Youden index of the ROC curve. Taking the discrimination diagnosis between normal people and patients infected with the new coronavirus at different stages of the disease as an example, the Youden index and the corresponding threshold are shown in Table 1. Table 1 shows the threshold, sensitivity, specificity and Youden index of patients infected with the new coronavirus at different stages of the disease relative to the normal group.

[0069] Table 1

[0070]

[0071]

[0072]

[0073]

[0074]

[0075] Among them, 52 of the 181 sera from patients with novel coronavirus infection of different disease courses were tested for novel coronavirus nucleic acid on the same day of serum sample collection. After excluding 28 samples tested after nucleic acid turned negative before discharge, 7 of the remaining 24 samples (29%) still had negative results for novel coronavirus nucleic acid, while the detection sensitivity of PLGLB1 protein in serum samples of the same period was 95.8% and the specificity was 100%. Before the nucleic acid test turned negative continuously, most patients had fluctuating results of nucleic acid test, while PLGLB1 protein could maintain extremely high detection sensitivity in serum samples at any stage of the disease. The results show that compared with the novel coronavirus nucleic acid test, PLGLB1 protein has higher detection sensitivity and stability for novel coronavirus infected patients.

[0076] PRM validation of PLGLB1 protein was performed in the serum of a patient infected with the novel coronavirus and a normal person, and the peptide quantification results are shown in Table 2. Table 2 shows the PRM quantification results. The results showed that the abundance of PLGLB1 in the serum of the patient infected with the novel coronavirus was higher than that in the serum of normal people, indicating that the TMT results are reliable and that the protein can be detected by the PRM targeted detection method.

[0077] Table 2

[0078]

[0079] For the peptide EQQCVIMAENR (SEQ ID NO: 2) with the largest signal intensity among the two peptides mentioned above, a quantitative standard curve was established using its stable isotope labeled standard peptide. The standard curve established with the peptide log2 (mass) as the abscissa and log2 (peak area) as the ordinate is as follows: Figure 5 The PRM quantitative results of the peptide in the serum of a patient infected with the novel coronavirus and a normal person were substituted into the standard curve. The calculation results showed that the concentration of the peptide EQQCVIMAENR (SEQ ID NO: 2) in the serum of a patient infected with the novel coronavirus was 0.64 μg / ml, corresponding to a PLGLB1 protein concentration of 0.47 μmol / L; the concentration of the peptide EQQCVIMAENR (SEQ ID NO: 2) in the serum of a normal person was 0.20 μg / ml, corresponding to a PLGLB1 protein concentration of 0.14 μmol / L.

[0080] From the above results, it can be seen that PLGLB1 protein in serum can be used as a candidate marker for distinguishing and diagnosing normal people from patients infected with the new coronavirus, as well as patients with fever / cough and patients infected with the new coronavirus. Moreover, PLGLB1 protein can be used as a serum diagnostic marker for patients infected with the new coronavirus throughout the entire course of the disease, and has better sensitivity and stability than the new coronavirus nucleic acid detection.

[0081] The preferred embodiments of the present disclosure are described in detail above in conjunction with the accompanying drawings; however, the present disclosure is not limited to the specific details in the above embodiments. Within the technical concept of the present disclosure, a variety of simple modifications can be made to the technical solution of the present disclosure, and these simple modifications all fall within the protection scope of the present disclosure.

[0082] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present disclosure will not further describe various possible combinations.

[0083] In addition, various embodiments of the present disclosure may be arbitrarily combined, and as long as they do not violate the concept of the present disclosure, they should also be regarded as the contents disclosed by the present disclosure.

Claims

1. A mass spectrometry-based system for screening and diagnosing novel coronavirus infection, characterized in that: The system includes a device for detecting PLGLB1 protein, wherein the device for detecting PLGLB1 protein includes a mass spectrometer, wherein the mass spectrometer is configured to be capable of performing qualitative and quantitative detection of proteins using a tandem mass tagging (TMT) method and / or a targeted quantitative method; The system also includes a computing device, an input device for inputting the expression amount of the PLGLB1 protein, and an output device for outputting the discrimination between normal people and patients infected with the novel coronavirus at different stages of the disease; wherein the computing device includes a memory and a processor, the memory stores a computer program, and the processor is configured to execute the computer program stored in the memory to achieve the following discrimination: If the relative content of PLGLB1 protein in the blood sample of the person to be tested who does not have fever and / or cough symptoms is greater than or equal to 0.67, the person to be tested who does not have fever / cough symptoms is determined to be a patient or candidate for novel coronavirus infection; and / or, If the relative content of PLGLB1 protein in the serum of the person to be tested with fever and / or cough symptoms is greater than or equal to 0.77, the person to be tested with fever and / or cough symptoms is determined to be a patient or candidate for novel coronavirus infection; The relative content is defined as the ratio of the abundance of PLGLB1 protein in a sample divided by the average abundance of the protein; the average abundance refers to the abundance in a mixed sample using a tandem mass tagging (TMT) method.

2. Use of the material for detecting PLGLB1 protein in the system of claim 1 in the preparation of a kit for screening and diagnosis of novel coronavirus infection.

3. The use according to claim 2, wherein The material for detecting PLGLB1 protein is a material capable of detecting PLGLB1 protein in a sample from human blood.

4. The use according to claim 3, wherein The kit contains at least one of a colloidal gold test strip, an ELISA reagent, a chemiluminescent reagent, etc., and the material for detecting PLGLB1 protein is at least one of an antibody against PLGLB1 protein or peptide segment, a nucleic acid aptamer that specifically binds to PLGLB1 protein or peptide segment, a peptide nucleic acid that specifically binds to PLGLB1 protein or peptide segment, other substances that can specifically bind to PLGLB1 protein or peptide segment, and a PLGLB1 protein or peptide segment standard.

5. Use of the device for detecting PLGLB1 protein in the system of claim 1 in preparing a system for screening and diagnosis of novel coronavirus infection.

6. The use according to claim 5, wherein The device for detecting PLGLB1 protein is a device capable of detecting PLGLB1 protein in a sample from human blood.

7. The use according to claim 6, wherein The device for detecting PLGLB1 protein comprises a mass spectrometer, and the mass spectrometer is configured to be capable of performing qualitative and quantitative detection of proteins using a TMT method and / or a PRM / MRM / SRM method.

8. The use according to claim 7, wherein The amino acid sequence of the PLGLB1 protein is shown in SEQ ID NO:

1. When the tandem mass tagging (TMT) method is used, the peptide segment detected is the peptide segment of the PLGLB1 protein; When the PRM / MRM / SRM method is used for qualitative and quantitative detection of proteins, the detected matching peptides include unique peptides of the PLGLB1 protein, and the amino acid sequence of the unique peptides of the PLGLB1 protein includes but is not limited to SEQ ID NO: 2 and SEQ ID NO:

3.

9. Use of the stable isotope label in the system of claim 1 in the preparation of standard peptides in a kit based on mass spectrometry for screening and diagnosis of novel coronavirus infection, wherein: The stable isotope labeling includes: arginine R is labeled with C13 and / or N15, and / or lysine K is labeled with C13 and / or N15; the amino acid sequence of the standard peptide segment is a fragment of the amino acid sequence of the PLGLB1 protein.